139 related articles for article (PubMed ID: 10336580)
1. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
Cai WM; Chen B; Cai MH; Chen Y; Zhang YD
Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
Cai WM; Chen B; Cai MH; Zhang YD
Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
Cai WM; Chen B; Zhou Y; Zhang YD
Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
Chen B; Cai WM
Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
Rouini MR; Afshar M
Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
[TBL] [Abstract][Full Text] [Related]
6. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
8. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis.
Tran QT; Baek IH; Han NY; Yun HY; Chae JW
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890339
[TBL] [Abstract][Full Text] [Related]
9. Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4.
Afshar M; Thormann W
Electrophoresis; 2006 Apr; 27(8):1526-36. PubMed ID: 16609933
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers.
Chen X; Zhong D; Blume H
Eur J Pharm Sci; 2000 Mar; 10(1):11-6. PubMed ID: 10699379
[TBL] [Abstract][Full Text] [Related]
11. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
12. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
Dilger K; Meisel P; Hofmann U; Eichelbaum M
Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase.
Pires de Abreu LR; Lanchote VL; Bertucci C; Cesarino EJ; Bonato PS
J Pharm Biomed Anal; 1999 Jun; 20(1-2):209-16. PubMed ID: 10704025
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective assay of S+ - and R- -propafenone in human urine by using RP-HPLC with pre-column chiral derivatization.
Wu YJ; Ma MM; Zheng S
J Zhejiang Univ Sci; 2004 Feb; 5(2):226-9. PubMed ID: 14674037
[TBL] [Abstract][Full Text] [Related]
15. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
Anzenbacherová E; Anzenbacher P; Perlik F; Kvetina J
Int J Clin Pharmacol Ther; 2000 Sep; 38(9):426-9. PubMed ID: 11020029
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective determination of propafenone and its metabolites in human plasma by liquid chromatography-mass spectrometry.
Zhong D; Chen X
J Chromatogr B Biomed Sci Appl; 1999 Jan; 721(1):67-75. PubMed ID: 10027638
[TBL] [Abstract][Full Text] [Related]
17. Effect of
Doki K; Shirayama Y; Sekiguchi Y; Aonuma K; Kohda Y; Ieda M; Homma M
Pharmacogenomics; 2020 Dec; 21(18):1279-1288. PubMed ID: 33203295
[No Abstract] [Full Text] [Related]
18. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
Cai WM; Zhang YD; Chen B; Cai MH; Luo JP; Ling SS
Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.
Chow MS; White CM; Lau CP; Fan C; Tang MO
J Clin Pharmacol; 2001 Jan; 41(1):92-6. PubMed ID: 11144999
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
